HepaLife Technologies, Inc. (OTCBB: HPLF) is a development stage biotechnology company focused on the identification, development and eventual commercialization of cell-based technologies and products.

Current cell-based technologies under development by HepaLife include:

1. The first-of- its-kind artificial liver device,
2. Proprietary in-vitro toxicology and pre-clinical drug testing platforms, and
3. Cell-culture based vaccines to protect against the spread of influenza viruses among humans, including potentially the high pathogenicity H5N1 virus.